Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06725953 · ClinicalTrials.gov registry record · NA

Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes

A NA study of Cancer Survivorship and Chemotherapy Side Effects, sponsored by University of Oklahoma.

Recruiting
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT06725953 is a NA study of Cancer Survivorship and Chemotherapy Side Effects that is actively recruiting participants, run by University of Oklahoma. The registered enrollment target is 38 participants, below the 257-participant average among 11 other Cancer Survivorship trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06725953, a NA study of Cancer Survivorship and Chemotherapy Side Effects, is actively recruiting participants, sponsored by University of Oklahoma.

RECRUITING
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

The growing U.S. cancer survivor population is projected to hit 26M by 2040. Chemotherapy represents an effective cancer treatment but can diminish cancer survivors' quality of life-particularly cognitive function-through select pathophysiological processes. Research on chemotherapy-induced cognitive impairment (hereafter, 'chemo-brain') is therefore critical. Chemotherapy disrupts immune system function and antioxidant regulation, causing inflammatory molecule release and damaging the brain's blood vessels. The brain's vascular function and, possibly, its neurons, are subsequently impaired-likely contributing to chemo-brain. Type 2 diabetes (T2D), a common cancer survivor comorbidity, shares underlying pathophysiology with chemo-brain. T2D-related insulin resistance can precipitate repeated high blood sugar episodes which increase inflammatory molecule release. In individuals with T2D without cancer, negative relationships are observed between inflammatory molecule concentrations and the brain's vascular and/or cognitive function. Cancer survivors with T2D might thus have higher chemo-brain risk than those without T2D. Yet, more research must compare how the brain's vascular function, as well as cognitive, inflammatory, and cardiometabolic indices, differ between these groups. Physical activity (PA) counteracts chemo-brain's and T2D's pathophysiology, with higher PA/fitness resulting in better vascular function of the brain, lower inflammatory molecule concentrations, and improved insulin sensitivity. We are therefore conducting a 30-participant quasi-experimental pilot study in cancer survivors with (cases) and without (controls) T2D. We will first investigate between-group differences in the brain's vascular function as well as cognitive, inflammatory, cardiometabolic, and epigenetic outcomes. We will then examine between-group changes in these outcomes and select psychosocial metrics during a 12-week technology-based PA program-potentially further elucidating in

Interventions

  • BEHAVIORAL Social Cognitive Theory-based, Technology-delivered Physical Activity Program

Study Locations (1)

Oklahoma

  • University of Oklahoma Health Sciences - Oklahoma City

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2025-03-10
Est. Completion 2026-05
Phase NA

Sponsor

University of Oklahoma

358 total trials

What the Registry Record Tells You About NCT06725953

The ClinicalTrials.gov registry entry for NCT06725953 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 257-participant average among 11 other Cancer Survivorship trials with a reported enrollment target (85% lower). The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer Survivorship appearing as the primary indexed condition, and to 1 intervention - of which Social Cognitive Theory-based, Technology-delivered Physical Activity Program is the first listed.

NCT06725953 reports 1 study location spanning 1 distinct geographic area - top geographies include Oklahoma.

Frequently Asked Questions

What is clinical trial NCT06725953 about?

NCT06725953 is a clinical study titled "Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes". The growing U.S. cancer survivor population is projected to hit 26M by 2040. Chemotherapy represents an effective cancer treatment but can diminish cancer survivors' quality of life-particularly cognitive function-through select pathophysiological processes. Research on chemotherapy-induced cognitiv...

What is the current status of trial NCT06725953?

This trial is currently recruiting. It is a NA study. The enrollment target is 38 participants. The study started on 2025-03-10. Estimated completion is 2026-05.

What conditions does trial NCT06725953 study?

This clinical trial studies the following conditions: Cancer Survivorship, Chemotherapy Side Effects.

What interventions are being tested in trial NCT06725953?

The interventions under investigation include: Social Cognitive Theory-based, Technology-delivered Physical Activity Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06725953?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06725953 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer Survivorship

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.